好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The second clinical-pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene.
Movement Disorders
P3 - Poster Session 3 (5:30 PM-6:30 PM)
10-028

To describe the FTDP-17 family.

In 2006 a c.823-10G>T MAPT variant in intron 9 resulting in the inclusion of exon 10 in the MAPT transcript and overexpression of 4R tau was reported in a family with FTDP-17 (Malkani et al, 2006- single report to date).

 

The study submitted for AAN is the first study with autopsy results and the only other report of this variant to date.

Examination and MAPT Sanger: proband, two asymptomatic siblings.

MRI brain: proband.

Autopsy: proband, brother.

Clinical:

 

A 50-year-old man behaved inappropriately (diagnosed FTDP-17 at 61). He became wheelchair bound, anarthric and recently died (this allowed for the second autopsy analysis).

 

The proband’s brother became “odd” in his 40s, forgetful (diagnosed FTD, died at 59).

 

Brother: dementia in his 40s, “odd”, died at 53.

 

The proband’s sister and maternal aunt: forgetful,  vulgar.

 

The pro band’s mother: dementia in late 70s, father at 43 was forgetful, had sweet tooth and died at 53.

 

Radiological:

 

Proband MRI brain: very severe temporal and frontal lobes atrophy.

 

Neuropathological:

 

Proband: severe atrophy of the frontal and temporal lobes. Frequent tau pathology.  

 

Brother: Tau antibody staining- 4R tauopathy.

 

Western blot:

 

Brother: blots of the sarkosyl-insoluble tau extracted from three brain regions showed that the insoluble pathological tau was exclusively 4R-tau.

 

Sanger:

 

Proband: heterozygote for the splicing mutation c.823-10G>T at the intron 9/ exon 10 boundary of the tau (MAPT) gene. Not detected in two asymptomatic siblings.

 

 

 

C.823-10G>T is an intronic variant that probably strengthens the polypyrimidine tract thus affecting the splicing of exon 10 close to the 3’ splice site.

Up to now there has only been one family with three affected members carrying the C.823-10G>T MAPT variant. However there was no neuropathological data available. There has been no other families reported to confirm or refute c. 823-10G>T as a mutation.

 

 

 

 

Authors/Disclosures
Diana Angelika Olszewska, MD, PhD (Cork University Hospital)
PRESENTER
Dr. Olszewska has nothing to disclose.
Christopher McGuigan, MD (Department of Neurology, St. Vincent's University Hospital) An immediate family member of Prof. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Prof. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. The institution of Prof. McGuigan has received research support from Novartis.
Henry Houlden No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Michael Hutchinson, MD (St Vincent's University Hospital) Dr. Hutchinson has nothing to disclose.
Michael Hutton, PhD (Mayo Clinic Jacksonville) No disclosure on file
No disclosure on file
No disclosure on file
Francesca Brett No disclosure on file
No disclosure on file
Timothy Lynch, MD (Dublin Neurological Institute,) Dr. Lynch has nothing to disclose.